Oncology Peer Review On-The-Go: Improving Experience of LGBTQ+ Patients in Cancer Care

Podcast

This episode features Don Dizon, MD, discussing how LGBTQ+ patients with cancer navigate the world of cancer care, and the critical steps needed to improve their experiences.

This week, CancerNetwork® spoke with Don Dizon, MD, about certain unique challenges LGBTQ+ patients face when navigating through their cancer journey, and how providers can improve these experiences. Dizon, the director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, touched on overcoming barriers in clinical cancer research, creating a gender-affirming environment for patients, and other important topics for treating LGBTQ+ patients with cancer.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.
Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.
Jessica Cheng, MD, noted that working with patients in the field of cancer rehabilitation to improve recovery times brings her joy.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Related Content
FDA Approves Subcutaneous Atezolizumab Plus Hyaluronidase-tqjs in Multiple Soft Tumor Indications

FDA Approves Subcutaneous Atezolizumab Plus Hyaluronidase-tqjs in Multiple Soft Tumor Indications

Ariana Pelosci
September 12th 2024
Article

Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Exercise Treatment as Part of Multidisciplinary Whole Person Care in Oncology

Exercise Treatment as Part of Multidisciplinary Whole Person Care in Oncology

Neil M. Iyengar, MD
August 21st 2024
Article

Neil M. Iyengar, MD, highlights how to best integrate exercise oncology into multidisciplinary care.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Taking a “Cross-Cutting Approach” With Cancer Vaccinations

Catherine J. Wu, MD
August 12th 2024
Podcast

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

The FDA has set a Prescription Drug User Fee Act date of February 17, 2025, to approve vimseltinib for patients with tenosynovial giant cell tumor.

Vimseltinib Earns FDA Priority Review in Tenosynovial Giant Cell Tumor

Russ Conroy
August 16th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of February 17, 2025, to approve vimseltinib for patients with tenosynovial giant cell tumor.

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Adding Olanzapine to Antiemetic Therapy May Help With CINV Incidence

Roman Fabbricatore
August 4th 2024
Article

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.